Cellular Targeting of Oligonucleotides by Conjugation with Small Molecules

Drug candidates derived from oligonucleotides (ON) are receiving increased attention that is supported by the clinical approval of several ON drugs. Such therapeutic ON are designed to alter the expression levels of specific disease-related proteins, e.g., by displaying antigene, antisense, and RNA...

Full description

Bibliographic Details
Main Authors: Manuel Hawner, Christian Ducho
Format: Article
Language:English
Published: MDPI AG 2020-12-01
Series:Molecules
Subjects:
Online Access:https://www.mdpi.com/1420-3049/25/24/5963
id doaj-cfc9c0cde5b0490d8e719b847fa1870c
record_format Article
spelling doaj-cfc9c0cde5b0490d8e719b847fa1870c2020-12-17T00:04:37ZengMDPI AGMolecules1420-30492020-12-01255963596310.3390/molecules25245963Cellular Targeting of Oligonucleotides by Conjugation with Small MoleculesManuel Hawner0Christian Ducho1Department of Pharmacy, Pharmaceutical and Medicinal Chemistry, Saarland University, Campus C2 3, 66 123 Saarbrücken, GermanyDepartment of Pharmacy, Pharmaceutical and Medicinal Chemistry, Saarland University, Campus C2 3, 66 123 Saarbrücken, GermanyDrug candidates derived from oligonucleotides (ON) are receiving increased attention that is supported by the clinical approval of several ON drugs. Such therapeutic ON are designed to alter the expression levels of specific disease-related proteins, e.g., by displaying antigene, antisense, and RNA interference mechanisms. However, the high polarity of the polyanionic ON and their relatively rapid nuclease-mediated cleavage represent two major pharmacokinetic hurdles for their application in vivo. This has led to a range of non-natural modifications of ON structures that are routinely applied in the design of therapeutic ON. The polyanionic architecture of ON often hampers their penetration of target cells or tissues, and ON usually show no inherent specificity for certain cell types. These limitations can be overcome by conjugation of ON with molecular entities mediating cellular ‘targeting’, i.e., enhanced accumulation at and/or penetration of a specific cell type. In this context, the use of small molecules as targeting units appears particularly attractive and promising. This review provides an overview of advances in the emerging field of cellular targeting of ON via their conjugation with small-molecule targeting structures.https://www.mdpi.com/1420-3049/25/24/5963oligonucleotidesconjugationsmall moleculescellular targeting
collection DOAJ
language English
format Article
sources DOAJ
author Manuel Hawner
Christian Ducho
spellingShingle Manuel Hawner
Christian Ducho
Cellular Targeting of Oligonucleotides by Conjugation with Small Molecules
Molecules
oligonucleotides
conjugation
small molecules
cellular targeting
author_facet Manuel Hawner
Christian Ducho
author_sort Manuel Hawner
title Cellular Targeting of Oligonucleotides by Conjugation with Small Molecules
title_short Cellular Targeting of Oligonucleotides by Conjugation with Small Molecules
title_full Cellular Targeting of Oligonucleotides by Conjugation with Small Molecules
title_fullStr Cellular Targeting of Oligonucleotides by Conjugation with Small Molecules
title_full_unstemmed Cellular Targeting of Oligonucleotides by Conjugation with Small Molecules
title_sort cellular targeting of oligonucleotides by conjugation with small molecules
publisher MDPI AG
series Molecules
issn 1420-3049
publishDate 2020-12-01
description Drug candidates derived from oligonucleotides (ON) are receiving increased attention that is supported by the clinical approval of several ON drugs. Such therapeutic ON are designed to alter the expression levels of specific disease-related proteins, e.g., by displaying antigene, antisense, and RNA interference mechanisms. However, the high polarity of the polyanionic ON and their relatively rapid nuclease-mediated cleavage represent two major pharmacokinetic hurdles for their application in vivo. This has led to a range of non-natural modifications of ON structures that are routinely applied in the design of therapeutic ON. The polyanionic architecture of ON often hampers their penetration of target cells or tissues, and ON usually show no inherent specificity for certain cell types. These limitations can be overcome by conjugation of ON with molecular entities mediating cellular ‘targeting’, i.e., enhanced accumulation at and/or penetration of a specific cell type. In this context, the use of small molecules as targeting units appears particularly attractive and promising. This review provides an overview of advances in the emerging field of cellular targeting of ON via their conjugation with small-molecule targeting structures.
topic oligonucleotides
conjugation
small molecules
cellular targeting
url https://www.mdpi.com/1420-3049/25/24/5963
work_keys_str_mv AT manuelhawner cellulartargetingofoligonucleotidesbyconjugationwithsmallmolecules
AT christianducho cellulartargetingofoligonucleotidesbyconjugationwithsmallmolecules
_version_ 1724380723083739136